Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Algernon closes $177,000 first tranche of financing

By The Northwire Desk — AI Analysis Nov 14, 2025 · 20:03 AGN · 0.085 Algernon Health Inc
AGN · Price

Executive Summary

  • Algernon Health Inc. has closed the first tranche of its non-brokered private placement financing.
  • The company raised gross proceeds of $177,000 from the sale of 2,528,752 units.
  • Proceeds will be used to advance the Alzheimer's disease program, including opening the first U.S. AD clinic, and for general and administrative expenses.

Key Details

  • Transaction Structure: Non-brokered private placement.
  • Gross Proceeds: $177,000.
  • Units Sold: 2,528,752 units.
  • Issue Price: $0.07 per unit.
  • Insider Participation: Insiders participated in the amount of $37,000. This constitutes a related party transaction under Multilateral Instrument 61-101. The company relied on exemptions from valuation and minority shareholder approval requirements as the insider purchase did not exceed 25% of market capitalization.
  • Finders' Fees: No cash finders' fees were paid.
  • Use of Proceeds: Advancing the Alzheimer's disease (AD) program (including opening the first U.S. AD clinic), general and administrative expenses, and working capital.
  • Future Tranches: Additional tranches are expected to close on or before December 1, 2025.
  • Securities Restrictions: Securities are subject to a statutory hold period of four months plus one day from the date of issuance.

Notable Quotes

  • None provided in the text.
Read the original news release →

More from Algernon Health Inc

Mar 23, 2026 · 15:15

Algernon Health to open brain PET scanning clinic

Production / Operations Mar 23, 2026 · 07:00

Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building

Production / Operations Dec 31, 2025 · 16:01

Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing

Financings Dec 23, 2025 · 19:00

Algernon increases placement, closes third tranche

Financings Dec 23, 2025 · 16:01

Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche

Financings Nov 28, 2025 · 20:25

Algernon Health closes second tranche of financing

Financings